

HOUSE BILL 1026

C8

2lr2444

By: Delegates V. Turner, Braveboy, Cane, Costa, Donoghue, Elliott, Frank, Frush, Gaines, Healey, Holmes, Howard, Hubbard, Ivey, Kach, Kipke, Krebs, Morhaim, Nathan–Pulliam, Niemann, Oaks, Pena–Melnyk, Proctor, Ready, Reznik, B. Robinson, Ross, Rudolph, Summers, Tarrant, F. Turner, Valderrama, Vallario, Vaughn, and Walker

Introduced and read first time: February 10, 2012

Assigned to: Health and Government Operations

A BILL ENTITLED

1 AN ACT concerning

2 **Economic Development – Sickle Cell Disease Research Program**

3 FOR the purpose of establishing the Sickle Cell Disease Research Program to be
4 administered by the Maryland Technology Development Corporation to provide
5 grants for certain sickle cell disease research projects; establishing the purposes
6 of the Program; establishing the Sickle Cell Disease Research Fund in the
7 Corporation; providing for the purpose and composition of the Fund; requiring
8 the Executive Director of the Corporation or the Executive Director’s designee to
9 administer the Fund; requiring the State Treasurer to invest money in the
10 Fund; providing that earnings of the Fund shall be credited to the Fund;
11 establishing certain types of grants to be awarded under the Program; requiring
12 the Corporation to adopt certain regulations; requiring the Corporation to
13 include certain information in a certain report to the Governor and General
14 Assembly; exempting the Fund from a certain provision of law requiring
15 interest on State money in special funds to accrue to the General Fund of the
16 State; defining certain terms; and generally relating to the creation of a
17 program for sickle cell disease research.

18 BY adding to

19 Article – Economic Development

20 Section 10–454 through 10–459 to be under the new part “Part V. Sickle Cell
21 Disease Research Program”

22 Annotated Code of Maryland

23 (2008 Volume and 2011 Supplement)

24 BY repealing and reenacting, with amendments,

25 Article – State Finance and Procurement

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 Section 6–226(a)(2)(ii)62. and 63.
2 Annotated Code of Maryland
3 (2009 Replacement Volume and 2011 Supplement)

4 BY adding to
5 Article – State Finance and Procurement
6 Section 6–226(a)(2)(ii)64.
7 Annotated Code of Maryland
8 (2009 Replacement Volume and 2011 Supplement)

9 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
10 MARYLAND, That the Laws of Maryland read as follows:

11 **Article – Economic Development**

12 **10–452. RESERVED.**

13 **10–453. RESERVED.**

14 **PART V. SICKLE CELL DISEASE RESEARCH PROGRAM.**

15 **10–454.**

16 (A) IN THIS PART THE FOLLOWING WORDS HAVE THE MEANINGS
17 INDICATED.

18 (B) “FUND” MEANS THE SICKLE CELL DISEASE RESEARCH FUND
19 ESTABLISHED UNDER § 10–456 OF THIS SUBTITLE.

20 (C) “PROGRAM” MEANS THE SICKLE CELL DISEASE RESEARCH
21 PROGRAM ESTABLISHED UNDER § 10–455 OF THIS SUBTITLE.

22 **10–455.**

23 (A) **THERE IS A SICKLE CELL DISEASE RESEARCH PROGRAM.**

24 (B) **THE PURPOSE OF THE PROGRAM IS TO:**

25 (1) **PROMOTE MILESTONE–DRIVEN TRANSLATIONAL RESEARCH**
26 **USING BONE MARROW AND UMBILICAL CORD BLOOD TO DEVELOP CURES FOR**
27 **SICKLE CELL DISEASE; AND**

28 (2) **ESTABLISH THE STATE AS A KEY LOCATION FOR SICKLE CELL**
29 **DISEASE RESEARCH AND TREATMENT.**

1 **(C) THE CORPORATION SHALL ADMINISTER THE PROGRAM.**

2 **10-456.**

3 **(A) THERE IS A SICKLE CELL DISEASE RESEARCH FUND IN THE**
4 **CORPORATION.**

5 **(B) THE PURPOSE OF THE FUND IS TO PROVIDE GRANTS AND LOANS TO**
6 **PUBLIC AND PRIVATE ENTITIES IN THE STATE TO DEVELOP CURES FOR SICKLE**
7 **CELL DISEASE USING BONE MARROW AND UMBILICAL CORD BLOOD.**

8 **(C) (1) THE FUND IS A SPECIAL, NONLAPSING FUND THAT IS NOT**
9 **SUBJECT TO § 7-302 OF THE STATE FINANCE AND PROCUREMENT ARTICLE.**

10 **(2) THE STATE TREASURER SHALL HOLD THE FUND**
11 **SEPARATELY, AND THE COMPTROLLER SHALL ACCOUNT FOR THE FUND.**

12 **(D) THE FUND CONSISTS OF:**

13 **(1) MONEY APPROPRIATED IN THE STATE BUDGET TO THE FUND;**
14 **AND**

15 **(2) ANY OTHER MONEY FROM ANY OTHER SOURCE ACCEPTED FOR**
16 **THE BENEFIT OF THE FUND.**

17 **(E) THE EXECUTIVE DIRECTOR OF THE CORPORATION, OR THE**
18 **EXECUTIVE DIRECTOR'S DESIGNEE, SHALL ADMINISTER THE FUND IN**
19 **ACCORDANCE WITH THIS PART AND OTHER APPLICABLE LAW.**

20 **(F) THE FUND SHALL BE USED TO COVER THE COSTS OF THE**
21 **PROGRAM, INCLUDING ANY GRANTS AND LOANS THAT ARE AWARDED TO**
22 **ELIGIBLE RECIPIENTS.**

23 **(G) (1) THE STATE TREASURER SHALL INVEST THE MONEY OF THE**
24 **FUND IN THE SAME MANNER AS OTHER STATE MONEY MAY BE INVESTED.**

25 **(2) ANY INVESTMENT EARNINGS OF THE FUND SHALL BE**
26 **CREDITED TO THE FUND.**

27 **(H) (1) THE GOVERNOR MAY INCLUDE IN THE STATE BUDGET BILL**
28 **FOR EACH FISCAL YEAR AN APPROPRIATION TO THE FUND.**

1 63. Transportation Trust Fund; AND

2 **64. SICKLE CELL DISEASE RESEARCH FUND.**

3 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
4 October 1, 2012.